Department of Nephrology, Hospital Universitari Bellvitge and Bellvitge Research Institute (IDIBELL), L'Hospitalet de Llobregat, C/Feixa llarga, s/n, Barcelona, 08907, Spain.
BigData and Artificial Intelligence Group (BigSEN Working Group) from the Spanish Society of Nephrology (SENEFRO), Santander, Spain.
BMC Nephrol. 2024 Aug 27;25(1):276. doi: 10.1186/s12882-024-03724-6.
Current research in nephrology is increasingly focused on elucidating the complexity inherent in tightly interwoven molecular systems and their correlation with pathology and related therapeutics, including dialysis and renal transplantation. Rapid advances in the omics sciences, medical device sensorization, and networked digital medical devices have made such research increasingly data centered. Data-centric science requires the support of computationally powerful and sophisticated tools able to handle the overflow of novel biomarkers and therapeutic targets. This is a context in which artificial intelligence (AI) and, more specifically, machine learning (ML) can provide a clear analytical advantage, given the rapid advances in their ability to harness multimodal data, from genomic information to signal, image and even heterogeneous electronic health records (EHR). However, paradoxically, only a small fraction of ML-based medical decision support systems undergo validation and demonstrate clinical usefulness. To effectively translate all this new knowledge into clinical practice, the development of clinically compliant support systems based on interpretable and explainable ML-based methods and clear analytical strategies for personalized medicine are imperative. Intelligent nephrology, that is, the design and development of AI-based strategies for a data-centric approach to nephrology, is just taking its first steps and is by no means yet close to its coming of age. These first steps are not even homogeneously taken, as a digital divide in access to technology has become evident between developed and developing countries, also affecting underrepresented minorities. With all this in mind, this editorial aim to provide a selective overview of the current use of AI technologies in nephrology and heralds the "Artificial Intelligence in Nephrology" special issue launched by BMC Nephrology.
当前肾脏病学的研究越来越侧重于阐明紧密交织的分子系统中固有的复杂性,以及它们与病理学和相关治疗学(包括透析和肾移植)的相关性。组学科学、医疗设备传感器化和联网的数字医疗设备的快速发展使得此类研究越来越以数据为中心。数据中心科学需要计算能力强大且复杂的工具的支持,这些工具能够处理新型生物标志物和治疗靶点的溢出。在这种情况下,人工智能(AI),更具体地说,机器学习(ML)可以提供明显的分析优势,因为它们能够快速利用从基因组信息到信号、图像甚至异构电子健康记录(EHR)的多种模态数据。然而,矛盾的是,只有一小部分基于 ML 的医学决策支持系统经过验证并证明具有临床实用性。为了将所有这些新知识有效地转化为临床实践,必须开发基于可解释和可解释的基于 ML 的方法和针对个性化医疗的清晰分析策略的临床合规支持系统。智能肾脏病学,即基于 AI 的策略的设计和开发,用于肾脏病学的数据中心方法,才刚刚迈出第一步,而且还远未达到成熟阶段。这些第一步甚至没有统一采取,因为在获得技术方面,发达国家和发展中国家之间已经出现了明显的数字鸿沟,这也影响到代表性不足的少数群体。考虑到所有这些,本社论旨在选择性地概述 AI 技术在肾脏病学中的当前应用,并预示着 BMC 肾脏病学推出的“肾脏病学中的人工智能”特刊。